The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 and $1.09, further underscoring its momentum heading into the new year.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of

Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of Abbott Laboratories (ABT)’s shares, while financial institutions hold 76.57%.

Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday. The company’s